Competitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Microenvironment

Publisher: La Merie Publishing
Pages: 38
Format: PDF and Online
Product Line:
Competitor Analysis
Product Line:
Target Pipeline
Product Code: LMCA0147
Release Date: December of 2016

200.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Microenvironment

This industry report describes the competitive R&D landscape of specific IDO and TDO inhibitors as well as dual target IDO & TDO inhibitors for modulation of the immunosuppressive tumor microenvironment as of December 2016. Selective and dual target novel indoleamine 2,3-dioxygenase (IDO) inhibitors and tryptophan 2,3-dioxygenase (TDO) inhibitors are being evaluated as single agents as well as in combination studies with other immune checkpoint modulators.

Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of IDO & TDO inhibitors for modulation of the tumor microenvironment. In addition, the report lists company-specific R&D pipelines of IDO & TDO inhibitors. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Competitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Microenvironment

Table of Contents

1) IDO & TDO Inhibitors

  • Epacadostat Studies – monotherapy & combinations
  • Indoximod Studies – monotherapy & combinations
  • Novel Indoleamine 2,3-Dioxygenase (IDO) Inhibitors
  • Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors
  • Dual IDO & TDO Inhibitors

2) Corporate IDO & TDO Inhibitor Pipelines

The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up